Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now later-stage tilt small index

Cardiac Amyloidosis: later-stage trial registry

7 of 9 indexed Cardiac Amyloidosis trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 7 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Cardiac Amyloidosis: 9 US clinical trials tracked, 7 recruiting.

Cardiac Amyloidosis is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Sharmila Dorbala, running 1 of these trials.

Enrollment posture brief

Registry condition cardiac-amyloidosis

OPEN 7 | RECR 78% | LATE 3 | EARLY 1 | RANK #1916 | SPON 1

Nearest open-share peer: Advanced Colorectal Carcinoma (78% recruiting · 9 trials)

Cardiac Amyloidosis (this)78%Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Cardiac Amyloidosis

Cardiac Amyloidosis lists 7 open slots (78% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cardiac Amyloidosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cardiac Amyloidosis is recruiting above its size-band peers.

    7 of 9 indexed trials (77.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cardiac Amyloidosis trials is spread across many organizations.

    Sharmila Dorbala accounts for 1 of 9 trials (11.1%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cardiac Amyloidosis enrolment sits around 200 participants.

    Median target enrolment is 200 among the 9 trials that report a genuine target (sentinel values excluded). 3 of those (33.3%) plan for fewer than 100 participants.

  4. Cardiac Amyloidosis splits between interventional and observational designs.

    5 interventional and 4 observational studies make up this index (55.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 33

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 3

Named interventions

Most-linked intervention names on Cardiac Amyloidosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

18F-Florbetaben (Neuraceq®) PET/MRI Drug
1 trials
I-124 evuzamitide Drug
1 trials
[18F]florbetaben Drug
1 trials
[68Ga]CBP8 PET/MRI Drug
1 trials
Tc99-PYP or Tc99-HDMP Scan Diagnostic test
1 trials
EchoNet-LVH screening for cardiac amyloidosis Other
1 trials
• Cardiac Rehabilitation Behavioral
1 trials

US sites by state

Facility locations filed on Cardiac Amyloidosis trials. A trial with sites in several states counts in each.

Massachusetts 4 trials
California 4 trials
New York 3 trials
Ohio 2 trials
North Carolina 2 trials
Minnesota 2 trials
Wisconsin 1 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cardiac Amyloidosis page

9 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 7 Cardiac Amyloidosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Sharmila Dorbala sponsors the most Cardiac Amyloidosis trials on record, review their full trial history before evaluating a specific study. See Sharmila Dorbala's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cardiac Amyloidosis condition card totals 9 registered trials; most-linked intervention 18F-Florbetaben (Neuraceq®) PET/MRI; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.